StreetInsider.com News Articles

Genomma Lab Internacional Announces Results for the Second Quarter 2026

Wed, 22 Jul 2026 20:03:00 -0400

MEXICO CITY, July 22, 2026 /PRNewswire/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) ("Genomma" or "the Company"), today announced its results for the second quarter 2026. All figures included herein are stated in nominal Mexican pesos and have been prepared in accordance with International Financial Reporting Standards (IFRS), unless otherwise noted.

Comments from Genomma's CEO, Marco Sparvieri

"Q2 2026 marked a sequential improvement in Mexico as our initiatives began to gain traction. Sell-in declined 4.4% and sell-out declined 4.0%, reflecting continued market softness while Genomma's market share

Genomma Lab Internacional Announces Results for the Second Quarter 2026

Wed, 22 Jul 2026 20:03:00 -0400

MEXICO CITY, July 22, 2026 /PRNewswire/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) ("Genomma" or "the Company"), today announced its results for the second quarter 2026. All figures included herein are stated in nominal Mexican pesos and have been prepared in accordance with International Financial Reporting Standards (IFRS), unless otherwise noted.

Comments from Genomma's CEO, Marco Sparvieri
"Q2 2026 marked a sequential improvement in Mexico as our initiatives began to gain traction. Sell-in declined 4.4% and sell-out declined 4.0%, reflecting continued market softness while Genomma's market share

Genomma Lab Internacional Announces Results for the Second Quarter 2026

Wed, 22 Jul 2026 20:03:00 -0400

MEXICO CITY, July 22, 2026 /PRNewswire/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) ("Genomma" or "the Company"), today announced its results for the second quarter 2026. All figures included herein are stated in nominal Mexican pesos and have been prepared in accordance with International Financial Reporting Standards (IFRS), unless otherwise noted.

Comments from Genomma's CEO, Marco Sparvieri
"Q2 2026 marked a sequential improvement in Mexico as our initiatives began to gain traction. Sell-in declined 4.4% and sell-out declined 4.0%, reflecting continued market softness while Genomma's market share

Genomma Lab Internacional Announces Results for the Second Quarter 2026

Wed, 22 Jul 2026 20:03:00 -0400

MEXICO CITY, July 22, 2026 /PRNewswire/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) ("Genomma" or "the Company"), today announced its results for the second quarter 2026. All figures included herein are stated in nominal Mexican pesos and have been prepared in accordance with International Financial Reporting Standards (IFRS), unless otherwise noted.

Comments from Genomma's CEO, Marco Sparvieri
"Q2 2026 marked a sequential improvement in Mexico as our initiatives began to gain traction. Sell-in declined 4.4% and sell-out declined 4.0%, reflecting continued market softness while Genomma's market share

Genomma Lab Internacional Announces Results for the Second Quarter 2026

Wed, 22 Jul 2026 20:03:00 -0400

MEXICO CITY, July 22, 2026 /PRNewswire/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) ("Genomma" or "the Company"), today announced its results for the second quarter 2026. All figures included herein are stated in nominal Mexican pesos and have been prepared in accordance with International Financial Reporting Standards (IFRS), unless otherwise noted.

Comments from Genomma's CEO, Marco Sparvieri
"Q2 2026 marked a sequential improvement in Mexico as our initiatives began to gain traction. Sell-in declined 4.4% and sell-out declined 4.0%, reflecting continued market softness while Genomma's market share

Genomma Lab Internacional Announces Results for the Second Quarter 2026

Wed, 22 Jul 2026 20:03:00 -0400

MEXICO CITY, July 22, 2026 /PRNewswire/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) ("Genomma" or "the Company"), today announced its results for the second quarter 2026. All figures included herein are stated in nominal Mexican pesos and have been prepared in accordance with International Financial Reporting Standards (IFRS), unless otherwise noted.

Comments from Genomma's CEO, Marco Sparvieri
"Q2 2026 marked a sequential improvement in Mexico as our initiatives began to gain traction. Sell-in declined 4.4% and sell-out declined 4.0%, reflecting continued market softness while Genomma's market share

Genomma Lab Internacional Announces Results for the Second Quarter 2026

Wed, 22 Jul 2026 20:03:00 -0400

MEXICO CITY, July 22, 2026 /PRNewswire/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) ("Genomma" or "the Company"), today announced its results for the second quarter 2026. All figures included herein are stated in nominal Mexican pesos and have been prepared in accordance with International Financial Reporting Standards (IFRS), unless otherwise noted.

Comments from Genomma's CEO, Marco Sparvieri
"Q2 2026 marked a sequential improvement in Mexico as our initiatives began to gain traction. Sell-in declined 4.4% and sell-out declined 4.0%, reflecting continued market softness while Genomma's market share

Genomma Lab Internacional Announces Results for the Second Quarter 2026

Wed, 22 Jul 2026 20:03:00 -0400

MEXICO CITY, July 22, 2026 /PRNewswire/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) ("Genomma" or "the Company"), today announced its results for the second quarter 2026. All figures included herein are stated in nominal Mexican pesos and have been prepared in accordance with International Financial Reporting Standards (IFRS), unless otherwise noted.

Comments from Genomma's CEO, Marco Sparvieri
"Q2 2026 marked a sequential improvement in Mexico as our initiatives began to gain traction. Sell-in declined 4.4% and sell-out declined 4.0%, reflecting continued market softness while Genomma's market share

Genomma Lab Internacional Announces Results for the Second Quarter 2026

Wed, 22 Jul 2026 20:03:00 -0400

MEXICO CITY, July 22, 2026 /PRNewswire/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) ("Genomma" or "the Company"), today announced its results for the second quarter 2026. All figures included herein are stated in nominal Mexican pesos and have been prepared in accordance with International Financial Reporting Standards (IFRS), unless otherwise noted.

Comments from Genomma's CEO, Marco Sparvieri
"Q2 2026 marked a sequential improvement in Mexico as our initiatives began to gain traction. Sell-in declined 4.4% and sell-out declined 4.0%, reflecting continued market softness while Genomma's market share

Genomma Lab Internacional Announces Results for the Second Quarter 2026

Wed, 22 Jul 2026 20:03:00 -0400

MEXICO CITY, July 22, 2026 /PRNewswire/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) ("Genomma" or "the Company"), today announced its results for the second quarter 2026. All figures included herein are stated in nominal Mexican pesos and have been prepared in accordance with International Financial Reporting Standards (IFRS), unless otherwise noted.

Comments from Genomma's CEO, Marco Sparvieri
"Q2 2026 marked a sequential improvement in Mexico as our initiatives began to gain traction. Sell-in declined 4.4% and sell-out declined 4.0%, reflecting continued market softness while Genomma's market share

Genomma Lab Internacional Announces Results for the Second Quarter 2026

Wed, 22 Jul 2026 20:03:00 -0400

MEXICO CITY, July 22, 2026 /PRNewswire/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) ("Genomma" or "the Company"), today announced its results for the second quarter 2026. All figures included herein are stated in nominal Mexican pesos and have been prepared in accordance with International Financial Reporting Standards (IFRS), unless otherwise noted.

Comments from Genomma's CEO, Marco Sparvieri
"Q2 2026 marked a sequential improvement in Mexico as our initiatives began to gain traction. Sell-in declined 4.4% and sell-out declined 4.0%, reflecting continued market softness while Genomma's market share

Genomma Lab Internacional Announces Results for the Second Quarter 2026

Wed, 22 Jul 2026 20:03:00 -0400

MEXICO CITY, July 22, 2026 /PRNewswire/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) ("Genomma" or "the Company"), today announced its results for the second quarter 2026. All figures included herein are stated in nominal Mexican pesos and have been prepared in accordance with International Financial Reporting Standards (IFRS), unless otherwise noted.

Comments from Genomma's CEO, Marco Sparvieri
"Q2 2026 marked a sequential improvement in Mexico as our initiatives began to gain traction. Sell-in declined 4.4% and sell-out declined 4.0%, reflecting continued market softness while Genomma's market share

Genomma Lab Internacional Announces Results for the Second Quarter 2026

Wed, 22 Jul 2026 20:03:00 -0400

MEXICO CITY, July 22, 2026 /PRNewswire/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) ("Genomma" or "the Company"), today announced its results for the second quarter 2026. All figures included herein are stated in nominal Mexican pesos and have been prepared in accordance with International Financial Reporting Standards (IFRS), unless otherwise noted.

Comments from Genomma's CEO, Marco Sparvieri
"Q2 2026 marked a sequential improvement in Mexico as our initiatives began to gain traction. Sell-in declined 4.4% and sell-out declined 4.0%, reflecting continued market softness while Genomma's market share

Genomma Lab Internacional Announces Results for the Second Quarter 2026

Wed, 22 Jul 2026 20:03:00 -0400

MEXICO CITY, July 22, 2026 /PRNewswire/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) ("Genomma" or "the Company"), today announced its results for the second quarter 2026. All figures included herein are stated in nominal Mexican pesos and have been prepared in accordance with International Financial Reporting Standards (IFRS), unless otherwise noted.

Comments from Genomma's CEO, Marco Sparvieri
"Q2 2026 marked a sequential improvement in Mexico as our initiatives began to gain traction. Sell-in declined 4.4% and sell-out declined 4.0%, reflecting continued market softness while Genomma's market share

Genomma Lab Internacional Announces Results for the Second Quarter 2026

Wed, 22 Jul 2026 20:03:00 -0400

MEXICO CITY, July 22, 2026 /PRNewswire/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) ("Genomma" or "the Company"), today announced its results for the second quarter 2026. All figures included herein are stated in nominal Mexican pesos and have been prepared in accordance with International Financial Reporting Standards (IFRS), unless otherwise noted.

Comments from Genomma's CEO, Marco Sparvieri
"Q2 2026 marked a sequential improvement in Mexico as our initiatives began to gain traction. Sell-in declined 4.4% and sell-out declined 4.0%, reflecting continued market softness while Genomma's market share

Genomma Lab Internacional Announces Results for the Second Quarter 2026

Wed, 22 Jul 2026 20:03:00 -0400

MEXICO CITY, July 22, 2026 /PRNewswire/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) ("Genomma" or "the Company"), today announced its results for the second quarter 2026. All figures included herein are stated in nominal Mexican pesos and have been prepared in accordance with International Financial Reporting Standards (IFRS), unless otherwise noted.

Comments from Genomma's CEO, Marco Sparvieri
"Q2 2026 marked a sequential improvement in Mexico as our initiatives began to gain traction. Sell-in declined 4.4% and sell-out declined 4.0%, reflecting continued market softness while Genomma's market share

Genomma Lab Internacional Announces Results for the Second Quarter 2026

Wed, 22 Jul 2026 20:03:00 -0400

MEXICO CITY, July 22, 2026 /PRNewswire/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) ("Genomma" or "the Company"), today announced its results for the second quarter 2026. All figures included herein are stated in nominal Mexican pesos and have been prepared in accordance with International Financial Reporting Standards (IFRS), unless otherwise noted.

Comments from Genomma's CEO, Marco Sparvieri
"Q2 2026 marked a sequential improvement in Mexico as our initiatives began to gain traction. Sell-in declined 4.4% and sell-out declined 4.0%, reflecting continued market softness while Genomma's market share

Genomma Lab Internacional Announces Results for the Second Quarter 2026

Wed, 22 Jul 2026 20:03:00 -0400

MEXICO CITY, July 22, 2026 /PRNewswire/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) ("Genomma" or "the Company"), today announced its results for the second quarter 2026. All figures included herein are stated in nominal Mexican pesos and have been prepared in accordance with International Financial Reporting Standards (IFRS), unless otherwise noted.

Comments from Genomma's CEO, Marco Sparvieri
"Q2 2026 marked a sequential improvement in Mexico as our initiatives began to gain traction. Sell-in declined 4.4% and sell-out declined 4.0%, reflecting continued market softness while Genomma's market share

Genomma Lab Internacional Announces Results for the Second Quarter 2026

Wed, 22 Jul 2026 20:03:00 -0400

MEXICO CITY, July 22, 2026 /PRNewswire/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) ("Genomma" or "the Company"), today announced its results for the second quarter 2026. All figures included herein are stated in nominal Mexican pesos and have been prepared in accordance with International Financial Reporting Standards (IFRS), unless otherwise noted.

Comments from Genomma's CEO, Marco Sparvieri
"Q2 2026 marked a sequential improvement in Mexico as our initiatives began to gain traction. Sell-in declined 4.4% and sell-out declined 4.0%, reflecting continued market softness while Genomma's market share

Genomma Lab Internacional Announces Results for the Second Quarter 2026

Wed, 22 Jul 2026 20:03:00 -0400

MEXICO CITY, July 22, 2026 /PRNewswire/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) ("Genomma" or "the Company"), today announced its results for the second quarter 2026. All figures included herein are stated in nominal Mexican pesos and have been prepared in accordance with International Financial Reporting Standards (IFRS), unless otherwise noted.

Comments from Genomma's CEO, Marco Sparvieri
"Q2 2026 marked a sequential improvement in Mexico as our initiatives began to gain traction. Sell-in declined 4.4% and sell-out declined 4.0%, reflecting continued market softness while Genomma's market share

Genomma Lab Internacional Announces Results for the Second Quarter 2026

Wed, 22 Jul 2026 20:03:00 -0400

MEXICO CITY, July 22, 2026 /PRNewswire/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) ("Genomma" or "the Company"), today announced its results for the second quarter 2026. All figures included herein are stated in nominal Mexican pesos and have been prepared in accordance with International Financial Reporting Standards (IFRS), unless otherwise noted.

Comments from Genomma's CEO, Marco Sparvieri
"Q2 2026 marked a sequential improvement in Mexico as our initiatives began to gain traction. Sell-in declined 4.4% and sell-out declined 4.0%, reflecting continued market softness while Genomma's market share

Genomma Lab Internacional Announces Results for the Second Quarter 2026

Wed, 22 Jul 2026 20:03:00 -0400

MEXICO CITY, July 22, 2026 /PRNewswire/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) ("Genomma" or "the Company"), today announced its results for the second quarter 2026. All figures included herein are stated in nominal Mexican pesos and have been prepared in accordance with International Financial Reporting Standards (IFRS), unless otherwise noted.

Comments from Genomma's CEO, Marco Sparvieri
"Q2 2026 marked a sequential improvement in Mexico as our initiatives began to gain traction. Sell-in declined 4.4% and sell-out declined 4.0%, reflecting continued market softness while Genomma's market share

Genomma Lab Internacional Announces Long-Term Debt Refinancing Transaction

Wed, 22 Jul 2026 10:03:00 -0400

MEXICO CITY, July 22, 2026 /PRNewswire/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB) ("Genomma Lab" or "the Company"), one of the leading pharmaceutical and personal care product companies in Mexico with an expanding international reach, today announced it has entered into a long-term credit facility to refinance its existing financial liabilities.

As part of this refinancing, the Company secured a MXN 1.5 billion amortizing term loan with a 10-year maturity, replacing prior obligations with more favorable terms. Half of the facility has been drawn to date to retire

Genomma Lab Internacional Announces Long-Term Debt Refinancing Transaction

Wed, 22 Jul 2026 10:03:00 -0400

MEXICO CITY, July 22, 2026 /PRNewswire/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB) ("Genomma Lab" or "the Company"), one of the leading pharmaceutical and personal care product companies in Mexico with an expanding international reach, today announced it has entered into a long-term credit facility to refinance its existing financial liabilities.

As part of this refinancing, the Company secured a MXN 1.5 billion amortizing term loan with a 10-year maturity, replacing prior obligations with more favorable terms. Half of the facility has been drawn to date to retire

Genomma Lab Internacional Announces Long-Term Debt Refinancing Transaction

Wed, 22 Jul 2026 10:03:00 -0400

MEXICO CITY, July 22, 2026 /PRNewswire/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB) ("Genomma Lab" or "the Company"), one of the leading pharmaceutical and personal care product companies in Mexico with an expanding international reach, today announced it has entered into a long-term credit facility to refinance its existing financial liabilities.

As part of this refinancing, the Company secured a MXN 1.5 billion amortizing term loan with a 10-year maturity, replacing prior obligations with more favorable terms. Half of the facility has been drawn to date to retire